Therapeutics & the frontier

For decades the melanocortin system was a topic for physiology textbooks, not pharmacies. That has changed. Several agents are now approved, and what unites them is instructive: each targets a different receptor to treat adifferent disease, a direct demonstration that the same peptide family is reused across organs. The receptor pages explain the biology each one exploits — MC4R,MC1R, MC2R, and the wider system.

Setmelanotide (Imcivree) — MC4R

Setmelanotide is an MC4R agonist that restores signalling in the appetite circuit when the receptor's upstream inputs are missing. Its clearest benefit is therefore in obesity caused by deficienciesabove the receptor — in POMC, the processing enzyme PCSK1, or the leptin receptor (LEPR) — rather than in obesity from MC4R mutations themselves.^[1] It is given as a once-daily subcutaneous injection.

The approval history tracks the science outward from the rarest cases: the FDA cleared it in November 2020 for POMC, PCSK1, and LEPR deficiency, in 2022 for Bardet–Biedl syndrome, and in 2026 for acquired hypothalamic obesity.^[1][2] A characteristic and revealing side effect is skin darkening: setmelanotide is not perfectly selective, and partial activation of MC1R increases eumelanin — the same pigment mechanism that whole receptor page describes.^[1]

For the full story — how it repairs the appetite circuit, why it is not "the next Ozempic," and what the pivotal trial showed — see the dedicatedsetmelanotide explainer and the page onhypothalamic obesity, the condition behind its 2026 approval.

Afamelanotide (Scenesse) — MC1R

Afamelanotide is a synthetic analogue of α-MSH that binds predominantly toMC1R and drives eumelanin productionindependently of sunlight.^[4] That property is the whole point of its use: in erythropoietic protoporphyria (EPP), a rare inherited disorder, a build-up of protoporphyrin IX makes sunlight intensely painful, so building up protective pigment in advance lengthens the time patients can tolerate light.^[4]

The FDA approved it on 8 October 2019 — the first treatment for EPP — to increase pain-free light exposure in affected adults.^[3] It is unusual in form as well as mechanism: a 16 mg controlled-release implant placed under the skin by a trained clinician roughly every two months, rather than a pill or a self-injection.^[4]

Bremelanotide (Vyleesi) — central MCRs

Bremelanotide is a non-selective melanocortin agonist; at therapeutic doses its relevant activity is at MC1R and MC4R, and it is thought to act on MC4R-bearing circuits in the brain to influence sexual desire — a mechanism entirely different from blood-flow agents used for erectile dysfunction.^[5] The FDA approved it in June 2019 for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women, the first on-demand treatment for that condition.^[6]

It is a subcutaneous autoinjection taken as needed before anticipated activity. Its side-effect profile is a textbook illustration of melanocortin pharmacology: nausea is common, focal skin hyperpigmentation can occur, and each dose causes a transient rise in blood pressure with a fall in heart rate — which is why it is contraindicated in uncontrolled hypertension or known cardiovascular disease.^[5] Those cardiovascular effects are a recurring consideration across MC4R-active agents. For why the nausea and skin-darkening happen at all, see why melanocortin agonists make you queasy and tan; for its origin in the melanotan lineage, see thebremelanotide / PT-141 explainer.

Repository corticotropin (Acthar Gel) — the original

The oldest melanocortin medicine is also the one least often recognised as one. Repository corticotropin injection — a purified porcine ACTH preparation in a slow-release gelatin, marketed as Acthar Gel — has been used since the 1950s, long before the receptors were cloned. ACTH is itself a melanocortin peptide, so the drug is, in effect, a pan-melanocortin agonist.^[9] It is FDA-approved across a strikingly broad set of conditions, including infantile spasms in children under two, acute exacerbations of multiple sclerosis in adults, and symptomatic sarcoidosis, and is also used in nephrotic syndrome.^[9]

Its mechanism is the interesting part. The classic explanation is purely endocrine — ACTH drives MC2R in the adrenal cortex to release cortisol, so the drug was seen as an indirect steroid. But melanocortin receptors also sit on immune cells, and a proposed steroid-independent anti-inflammatory action through those receptors is now invoked to explain benefit in conditions where steroids alone underperform. How much of the clinical effect is steroid-independent is still debated, and the product has drawn scrutiny over cost — but conceptually it is the first proof that engaging this system treats disease.^[9][10] Synthetic ACTH fragments such as cosyntropin are used diagnostically, in the ACTH stimulation test of adrenal function.^[10]

Agonist or antagonist? Two ways to use one system

Most melanocortin medicines switch the system on. But because the pathway has a natural brake — AgRP opposing α-MSH — it can also be treated by blocking it, and that mirror-image strategy is therapeutically distinct.

The clearest example is wasting. In cancer, chronic kidney disease, and other serious illness, an overactive central melanocortin tone drives cachexia — appetite collapses and lean mass is lost. Setmelanotide's logic run in reverse applies here: an MC4R antagonist lifts appetite and preserves weight and lean mass. TCMCB07, a cyclic-peptide MC4R antagonist, does exactly this in models of cancer- and kidney-disease-associated cachexia and has moved into clinical testing.^[14] The same receptor, agonised for obesity and antagonised for wasting, captures how versatile the target is.

The frontier

Several directions are in active development — see the datedmelanocortin pipeline for the full picture:

• Oral MC1R agonists. Dersimelagon (MT-7117), a small-molecule oral MC1R agonist, raised symptom-free light exposure in a phase 2 trial in EPP/XLP, and its phase 3 programme (INSPIRE) reported a positive primary endpoint in 2026 — potentially an oral alternative to the afamelanotide implant. It is also being studied in diffuse cutaneous systemic sclerosis.^[7][13][8]
• Melanocortin agonists for inflammation. Palatin's PL-8177, an oral MC1R agonist, showed clinical remission in a small phase 2 ulcerative colitis study (33% vs 0% on placebo), though the trial was too small to prove significance.^[11] Its ophthalmic agonist PL-9643 met multiple sign endpoints in the phase 3 MELODY-1 trial for dry eye disease, with further phase 3 studies under way.^[12] Both pursue MC1R/MC3R's pro-resolving, anti-inflammatory actions rather than pigment or appetite.
• Next-generation and dual agonists. Work continues on selective and biased MC4R agonists aimed at appetite efficacy while minimising the blood-pressure liabilities of non-selective activation, and on dual MC3R/MC4R approaches to body weight.^[5] The same appetite circuit is where the GLP-1 weight drugs act — seeGLP-1 drugs and the appetite system.

Every route, one system

A striking feature of the field is how many forms these agents now take — and the route is not a detail. A controlled-release implant or an oral pill spreads exposure and softens the concentration peak that drives nausea, whereas a bolus injection maximises it. Approved and investigational melanocortin agents already span a daily injection (setmelanotide), a bimonthly implant (afamelanotide), an on-demand autoinjector (bremelanotide), an intramuscular gel (corticotropin), oral tablets (dersimelagon, PL-8177), and an eye drop (PL-9643). Why the peak matters is covered inwhy melanocortin agonists make you queasy and tan.

Indications, dosing, and eligibility are clinical decisions. This page describes mechanism and regulatory status for education only — it is not medical advice. See the editorial standards.

References

1. 1.StatPearls. Setmelanotide. NCBI Bookshelf (NBK589641). 2024. link ↗
2. 2.Rhythm Pharmaceuticals. FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity. Press release. 2026. link ↗
3. 3.HCPLive. FDA approves afamelanotide to treat erythropoietic protoporphyria. News. 2019. link ↗
4. 4.American College of Clinical Pharmacy. FDA approves SCENESSE implant for erythropoietic protoporphyria. News (mechanism & dosing). 2019. link ↗
5. 5.US FDA. VYLEESI (bremelanotide injection) prescribing information. Label, NDA 210557. 2019. link ↗
6. 6.Palatin Technologies / AMAG. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. Press release. 2019. link ↗
7. 7.Balwani M, et al. Erythropoietic protoporphyria: phase 2 trial of dersimelagon (MT-7117), an oral MC1R agonist. Blood. 136(Suppl 1):51. 2020. link ↗
8. 8.Kondo M, et al. Dersimelagon, a novel oral MC1R agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Review (PMC9434962). 2022. link ↗
9. 9.US FDA / DailyMed. ACTHAR (repository corticotropin injection) prescribing information. Label. 2024. link ↗
10. 10.Gong R. The renaissance of corticotropin therapy: melanocortin signalling beyond steroidogenesis. Review (H.P. Acthar Gel & cosyntropin, PMC2697107). 2009. link ↗
11. 11.Palatin Technologies. Positive topline phase 2 results: oral MC1R agonist PL-8177 in ulcerative colitis. Press release. 2025. link ↗
12. 12.Palatin Technologies. FDA confirms acceptability of remaining phase 3 trials for PL-9643 in dry eye disease. Press release. 2024. link ↗
13. 13.Tanabe Pharma America. Positive topline phase 3 (INSPIRE) results for dersimelagon in EPP and XLP. Press release. 2026. link ↗
14. 14.Zhu X, et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexia. J Clin Invest. 130(9):4921–34. 2020. link ↗